Kalaris Therapeutics, Inc.
KLRS
$2.56
$0.051.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 3.82M | 4.32M | 976.00K | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 12.26M | 10.35M | 4.19M | ||
| Operating Income | -12.26M | -10.35M | -4.19M | ||
| Income Before Tax | -11.35M | -10.20M | -5.65M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -11.35M | -10.20M | -5.65M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -11.35M | -10.20M | -5.65M | ||
| EBIT | -12.26M | -10.35M | -4.19M | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | -0.61 | -2.52 | -4.26 | ||
| Normalized Basic EPS | -0.38 | -1.57 | -2.66 | ||
| EPS Diluted | -0.61 | -2.52 | -4.26 | ||
| Normalized Diluted EPS | -0.38 | -1.57 | -2.66 | ||
| Average Basic Shares Outstanding | 18.70M | 4.05M | 1.33M | ||
| Average Diluted Shares Outstanding | 18.70M | 4.05M | 1.33M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||